MED
MEDIFAST INC
$12.69
+0.75%
$140.1M
No data for this timeframe.
Vol
Market Cap$140.1M
Cap SizeMicro Cap
Inst. Holders8 funds
Inst. Value$30.3M
Inst. Activity2 buys / 3 sells
Insider Activity3B / 0S
Insider Net $$241.7K
SEC Reports1
Press Releases4
Exchange NYSE·Sector Miscellaneous Food Preparations & Kindred Products·Inc. DE·CIK 0000910329·Prev Close $12.60
Recent Activity
May 21, 2026
Press
Medifast (MED) issued a press release highlighting OPTAVIA's clinical evidence differentiating its coach-guided metaboli
Impact 2/10
May 21, 2026
Press
Medifast (MED) issued a press release promoting the OPTAVIA coaching model, citing a 2019 randomized controlled trial sh
Impact 2/10
May 21, 2026
fda
Weight Loss Coaching vs. App-Only Programs: What Published Research Shows About Long-Term Outcomes
OPTAVIA, backed by 18 RCTs, shows coach-guided weight loss delivers up to 10x more weight loss and 1
May 11, 2026
Insider
SCHLACKMAN SCOTT bought 2,500 shares
Director @ $12.53 ($31.3K)
May 8, 2026
Insider
SCHLACKMAN SCOTT bought 2,500 shares
Director @ $12.65 ($31.6K)
May 4, 2026
SEC
Medifast reported Q1 2026 revenue of $76.0M, down 34.3% YoY, and a net loss of $0.19 per share, widening from a $0.07 lo
8-K — Impact 7/10
Mar 25, 2026
Insider
Chard Daniel R sold 20,095 shares
Chairman & CEO @ $9.59 ($192.7K)
Inst.
CHARLES SCHWAB INVESTMENT MANAGEMENT — ADD
776,829 shares ($8.3M)
Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$12.00 (Feb 2026)
Current $12.70
Low $12.00
Median $12.00
High $12.00
1 analysts
$12.00
$12.00
Analyst Ratings
0Strong Buy
0Buy
4Hold
4Sell
1Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Feb 19, 2026 | Stephens & Co. | MAINTAIN | Equal-Weight → Equal-Weight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.65 ▼ -51.2% | $-0.65 — $-0.65 | -395% YoY | 1 |
| Next Q | $-0.62 ▼ -63.2% | $-0.62 — $-0.62 | -195% YoY | 1 |
| Current FY | $-1.85 ▲ +6.6% | $-1.85 — $-1.85 | -9% YoY | 1 |
| Next FY | $-0.60 ▲ +78.3% | $-0.60 — $-0.60 | 68% YoY | 1 |
Latest Reports
NEUTRAL
Press
2/10
Medifast (MED) issued a press release highlighting OPTAVIA's clinical evidence differentiating its coach-guided metaboli
May 21, 2026
BEARISH
8-K
7/10
Medifast reported Q1 2026 revenue of $76.0M, down 34.3% YoY, and a net loss of $0.19 per share, widening from a $0.07 lo
May 4, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | $8.3M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $8.3M | ADD |
| VANGUARD GROUP INC | $7.6M | — |
| MORGAN STANLEY | $3.6M | TRIM |
| BANK OF AMERICA CORP | $1.0M | NEAR_EXIT |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 11, 2026 | SCHLACKMAN SCOTT | BUY | $31.3K |
| May 8, 2026 | SCHLACKMAN SCOTT | BUY | $31.6K |
| Mar 25, 2026 | Chard Daniel | F | $192.7K |
| Mar 25, 2026 | Chard Daniel | A | $0.00 |
| Mar 25, 2026 | Maloney James | F | $30.9K |
8 institutional holders with $30.3M total value (2,834,179 shares) as of 2025-Q4. Top holders: RENAISSANCE, CHARLES, VANGUARD. Net selling activity: 3 institutions trimmed/exited vs 2 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | RENAISSANCE TECHNOLOGIES LLC | 780,610 | $8.3M | 27.5% | — |
| 2 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 776,829 | $8.3M | 27.4% | ADD +30.5% |
| 3 | VANGUARD GROUP INC | 711,499 | $7.6M | 25.1% | — |
| 4 | MORGAN STANLEY | 334,858 | $3.6M | 11.8% | TRIM -43.1% |
| 5 | BANK OF AMERICA CORP /DE/ | 97,473 | $1.0M | 3.4% | NEAR_EXIT -78.5% |
| 6 | TWO SIGMA INVESTMENTS, LP | 80,340 | $858.0K | 2.8% | TRIM -64.9% |
| 7 | FMR LLC | 38,401 | $410.1K | 1.4% | ADD +28.0% |
| 8 | WELLS FARGO & COMPANY/MN | 14,169 | $151.3K | 0.5% | ADD +36.9% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 595,211 | 776,829 | +30.5% | $8.3M | 2025-Q4 |
| MORGAN STANLEY | TRIM | 588,539 | 334,858 | -43.1% | $3.6M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 452,543 | 97,473 | -78.5% | $1.0M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 228,799 | 80,340 | -64.9% | $858.0K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 10,348 | 14,169 | +36.9% | $151.3K | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 421,169 | 595,211 | +41.3% | $8.1M | 2025-Q3 |
| MORGAN STANLEY | ADD | 457,786 | 588,539 | +28.6% | $8.0M | 2025-Q3 |
| UBS Group AG | TRIM | 110,829 | 33,757 | -69.5% | $461.5K | 2025-Q3 |
| MORGAN STANLEY | ADD | 293,561 | 457,786 | +55.9% | $6.4M | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 265,572 | 421,169 | +58.6% | $5.9M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 288,515 | 396,369 | +37.4% | $5.6M | 2025-Q2 |
| UBS Group AG | ADD | 66,196 | 110,829 | +67.4% | $1.6M | 2025-Q2 |
| FMR LLC | ADD | 27,501 | 35,197 | +28.0% | $494.5K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 6,591 | 8,960 | +35.9% | $125.9K | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | DOUBLED | 114,138 | 265,572 | +132.7% | $3.6M | 2025-Q1 |
| UBS Group AG | TRIM | 92,182 | 66,196 | -28.2% | $892.3K | 2025-Q1 |
| UBS Group AG | DOUBLED | 6,316 | 92,182 | +1359.5% | $1.6M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 148,236 | — | $2.8M | 2024-Q3 |
4 unique insiders with 3 transactions. Net insider value: $241.7K ($241.7K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 11, 2026 | SCHLACKMAN SCOTT | Director | BUY | 2,500 | $12.53 | $31.3K |
| May 8, 2026 | SCHLACKMAN SCOTT | Director | BUY | 2,500 | $12.65 | $31.6K |
| Mar 25, 2026 | Chard Daniel R | Chairman & CEO | F | 20,095 | $9.59 | $192.7K |
| Mar 25, 2026 | Chard Daniel R | Chairman & CEO | A | 36,968 | $0.00 | $0.00 |
| Mar 25, 2026 | Maloney James P. | Chief Financial Officer | F | 3,224 | $9.59 | $30.9K |
| Mar 25, 2026 | Maloney James P. | Chief Financial Officer | A | 34,344 | $0.00 | $0.00 |
| Mar 25, 2026 | MacKenzie Jonathan Barrett | VP, Finance & CAO | F | 862 | $9.59 | $8.3K |
| Mar 25, 2026 | MacKenzie Jonathan Barrett | VP, Finance & CAO | A | 10,830 | $0.00 | $0.00 |
| Mar 20, 2026 | Chard Daniel R | Chairman & CEO | BUY | 17,678 | $10.11 | $178.7K |
| Mar 17, 2026 | Chard Daniel R | Chairman & CEO | F | 2,638 | $10.05 | $26.5K |
| Mar 17, 2026 | Maloney James P. | Chief Financial Officer | F | 482 | $10.05 | $4.8K |
| Mar 17, 2026 | MacKenzie Jonathan Barrett | VP, Finance & CAO | F | 70 | $10.05 | $703.50 |
| Mar 13, 2026 | Chard Daniel R | Chairman & CEO | F | 7,075 | $9.62 | $68.1K |
| Mar 13, 2026 | Maloney James P. | Chief Financial Officer | F | 918 | $9.62 | $8.8K |
| Mar 13, 2026 | MacKenzie Jonathan Barrett | VP, Finance & CAO | F | 198 | $9.62 | $1.9K |
1 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 0 neutral. Avg impact: 7.0/10.
NEUTRAL
2/10
Medifast (MED) issued a press release highlighting OPTAVIA's clinical evidence differentiating its c
May 21, 2026
NEUTRAL
2/10
Medifast (MED) issued a press release promoting the OPTAVIA coaching model, citing a 2019 randomized
May 21, 2026
NEUTRAL
2/10
Medifast (MED) issued a press release highlighting OPTAVIA's clinical research portfolio, including
May 15, 2026
NEUTRAL
2/10
Medifast issued a press release promoting OPTAVIA's clinical evidence for visceral fat reduction and
May 15, 2026
Historical analyst distribution (last covering-analyst action Feb 2026): 0% buy across 9 analysts — 0 strong buy, 0 buy, 4 hold, 4 sell, 1 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$12.00 mean target (Feb 2026)
$12.00 Low
$12.00 High
| Metric | Value |
|---|---|
| Current Price | $12.70 |
| Target Low | $12.00 |
| Target Mean | $12.00 |
| Target Median | $12.00 |
| Target High | $12.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.65 | $-0.65 | $-0.65 | -395.5% | -51.2% | 0↑ 1↓ | $0.1B | -31.1% | 1 |
| Next Q 2026-09-30 |
$-0.62 | $-0.62 | $-0.62 | -195.2% | -63.2% | 0↑ 1↓ | $0.1B | -24.3% | 1 |
| Current FY 2026-12-31 |
$-1.85 | $-1.85 | $-1.85 | -8.8% | +6.6% | 1↑ 0↓ | $0.3B | — | 1 |
| Next FY 2027-12-31 |
$-0.60 | $-0.60 | $-0.60 | 67.6% | +78.3% | 1↑ 0↓ | $0.3B | -8.5% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.650 | |
| 7d ago | $-0.430 | -0.220 |
| 30d ago | $-0.430 | -0.220 |
| 60d ago | $-0.430 | -0.220 |
| 90d ago | $-0.290 | -0.360 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Feb 19, 2026 | Stephens & Co. | MAINTAIN | Equal-Weight | Equal-Weight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 0 | 0 | 4 | 4 | 1 | 0% | |
| Apr 1, 2026 | 0 | 0 | 4 | 4 | 1 | 0% | |
| Mar 1, 2026 | 0 | 0 | 4 | 4 | 1 | 0% | |
| Feb 1, 2026 | 0 | 0 | 4 | 4 | 1 | 0% | |
| Jan 1, 2026 | 0 | 0 | 4 | 4 | 1 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 21, 2026
fda
Weight Loss Coaching vs. App-Only Programs: What Published Research Shows About Long-Term Outcomes
OPTAVIA, backed by 18 RCTs, shows coach-guided weight loss delivers up to 10x more weight loss and 17x more fat loss than app-only programs.
May 21, 2026
fda
The Human Layer in Weight Management: What OPTAVIA's Coaching Model Is Built to Do
OPTAVIA's coach-guided model delivers up to 10x more weight loss and 17x more fat loss than self-directed weight management, per peer-reviewed RCT.
May 15, 2026
fda
Peer-Reviewed Research Is Redefining Weight Loss Program Standards
Peer-reviewed research is redefining weight loss program standards, with OPTAVIA's RCT showing 98% lean mass preservation over 16 weeks.
May 15, 2026
fda
Peer-Reviewed Research Shows Structured Meal Replacement Programs Support Visceral Fat Reduction and Lean Mass Preservation
Peer-reviewed research shows OPTAVIA's structured meal replacement program reduces visceral fat 14% and preserves 98% lean mass over 16 weeks.
May 4, 2026
earnings_calendar
MED Q1 2026 Earnings Scheduled — 2026-05-04
Mar 23, 2026
short_interest
FTD: MED — 153,515 shares ($1.5M) failed to deliver
Settlement: 20260323, Price: $10.00, FTD Value: $1,535,150, MEDIFAST INC
Mar 13, 2026
short_interest
FTD: MED — 74,638 shares ($0.7M) failed to deliver
Settlement: 20260313, Price: $9.53, FTD Value: $711,300.14, MEDIFAST INC
Mar 12, 2026
short_interest
FTD: MED — 115,778 shares ($1.2M) failed to deliver
Settlement: 20260312, Price: $10.12, FTD Value: $1,171,673.36, MEDIFAST INC